Financial Report: AMRI

Recent acquisitions boost revenues

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI   3Q Revenues: $104.6 million (+67%) 3Q Loss: $4.2 million (loss of $8.6 million 3Q14) YTD Revenues: $275.9 million (+45%) YTD Loss: $4.1 million (loss of $1.4 million YTD14) Comments: Contract revenue for the quarter was $101.4 million, up 76%. Discovery and Development Services (DDS) contract revenue was up 35% to $23.1 million, primarily due to $4.6 million of incremental revenues from the acquisition of SSCI in February 2015. API contract revenue was up 84% to $56.2 millio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters